Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Cohen

Dermatology New York, NY Medical Doctor

NPI 1730179680 CMS profile 214828

550 1St Ave, 7 R, New York, NY 10016

Open in the dashboard

General payments

$2,961,968

606 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Cohen of New York, NY is reported in the CMS Open Payments database as having received $2,961,968 across 606 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $55,557 105
2024 General $104,410 135
2023 General $63,907 110
2022 General $36,230 68
2021 General $2,360,550 23
2020 General $166,315 36
2019 General $175,000 129

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Cohen
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to David Cohen were reported at $55,557. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year David Cohen Dermatology median Middle half National median
2019 $175,000 $454 $129–$1,240 $163
2020 $166,315 $235 $81–$756 $114
2021 $2,360,550 $377 $108–$1,108 $132
2022 $36,230 $514 $143–$1,391 $149
2023 $63,907 $607 $159–$1,674 $160
2024 $104,410 $751 $204–$1,903 $164
2025 $55,557 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Kadmon Corporation LLC $2,439,210 28 payments
  2. LEO Pharma Inc. $120,346 27 payments
  3. Dermira, Inc. $118,602 41 payments
  4. LEO Pharma AS $59,822 119 payments
  5. Ucb SA $49,952 32 payments
  6. AbbVie, Inc. $45,495 89 payments
  7. Incyte Corporation $22,921 73 payments
  8. Amgen Inc. $22,824 68 payments
  9. Pfizer Inc. $20,854 21 payments
  10. Janssen Global Services, LLC $14,956 23 payments
  11. Other $46,986 85 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Current or prospective ownership or investment interest $2,194,844 1 payment
  2. Consulting Fee $464,181 119 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $249,221 14 payments
  4. Travel and Lodging $23,469 217 payments
  5. Honoraria $18,252 9 payments
  6. Food and Beverage $12,001 246 payments
Products named General payments · program years 2019–2025
  1. QBREXZA $33,704 6 payments
  2. Bimzelx $33,256 14 payments
  3. TREMFYA $14,833 28 payments
  4. ADBRY $11,672 30 payments
  5. Enbrel Inflammation $10,701 41 payments
  6. Enbrel Inflammation $6,410 11 payments
  7. COSENTYX $4,320 1 payment
  8. NO PRODUCT DISCUSSED $2,930 9 payments
  9. Cimzia $2,909 3 payments
  10. ALTRENO $2,900 2 payments
  11. Other $4,136 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

238

Median for Dermatology: 534

Drug cost

$332,033

Median for Dermatology: $67,151

Branded share of claims

37.8%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 56 $205,975
Dupixent Syringe Dupilumab Brand 23 $106,797
Doxycycline Ir-Dr Doxycycline Monohydrate Brand 11 $12,820
Tacrolimus Generic 35 $3,029
Ciclopirox Generic 18 $1,121
Doxycycline Hyclate Generic 22 $760
Fluorouracil Generic 13 $733
Desonide Generic 25 $424
Mupirocin Generic 24 $224
Econazole Nitrate Generic 11 $151

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Enbrel
  • Amgen Inc. $8,155
$8,155 — —
Bimzelx
  • UCB, Inc. $4,900
  • UCB SA $74
$4,974 — —
OPZELURA
  • Incyte Corporation $205
$205 — —
VTAMA
  • Dermavant Sciences, Inc. $120
$120 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $72
$72 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

606 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record